 Matinas BioPharma Holdings, Inc. NYSE AMER: MTNB, today announced that it has commenced enrollment and started dosing patients in the ENHANCE-IT study and that it expects to resume dosing patients in the EnACT study imminently, following the recent receipt of necessary governmental and regulatory approvals in Uganda. Both studies had temporarily paused enrollment in March due to the COVID-19 pandemic. 